Centiva Capital’s Sarepta Therapeutics SRPT Stock Holding History

Centiva Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-149	Closed	-$14.4K	–	2228
2023 Q4	$14.4K	Buy	+149	New	+$14.3K	﹤0.01%	1682
2023 Q1	–	Sell	-1,930	Closed	-$250K	–	1825
2022 Q4	$250K	Buy	1,930 +1,630	+543%	+$189K	0.01%	1029
2022 Q3	$33K	Buy	+300	New	+$30.2K	﹤0.01%	1352
2020 Q3	–	Sell	-1,282	Closed	-$206K	–	865
2020 Q2	$206K	Buy	+1,282	New	+$174K	0.01%	522
2019 Q4	–	Sell	-6,184	Closed	-$466K	–	920
2019 Q3	$466K	Buy	+6,184	New	+$730K	0.03%	351

Other funds holding SRPT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Centiva Capital's SRPT Position: Q1 2024 in Review

Centiva Capital sold out of Sarepta Therapeutics (SRPT) in Q1 2024, closing a stake of 149 shares — an estimated $14.4K sold.

Centiva Capital first reported a position in SRPT in Q3 2019 and held it in 5 quarters. The position peaked at $466K in Q3 2019. 415 funds tracked by Wall St. Rank hold SRPT as of Q1 2024.

Centiva Capital reported no remaining Sarepta Therapeutics position as of Q1 2024 after selling out during the quarter.
Centiva Capital sold 149 Sarepta Therapeutics shares in Q1 2024, an estimated $14.4K.
Centiva Capital first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 5 quarters.
Centiva Capital's Sarepta Therapeutics position peaked at $466K in Q3 2019.
415 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2024.

Based on Centiva Capital's 13F filing for Q1 2024, filed 15 May 2024.